ADMA Biologics, Inc. (ADMA) Dividend History

Company News

• 3 Mid-Cap Medical Stocks Outperforming the Market

  Several mid-cap medical and biotechnology stocks have outperformed the broader market in 2025, including Penumbra Inc, TransMedics Group Inc, and ADMA Biologics Inc. These companies have shown strong momentum, bullish analyst sentiment, and potential for continued upside.

  Investing.com
• ADMA Biologics Statement on Tariffs

  ADMA Biologics, a U.S.-based biopharmaceutical company, has reiterated its strategic advantage through fully domestic manufacturing, commercialization, and supply chain operations. The company's vertically integrated U.S.-based infrastructure ensures supply chain robustness, regulatory compliance, and alignment with federal and private sector preferences for U.S.-made products.

  GlobeNewswire Inc.
• Is First Trust Small Cap Growth AlphaDEX ETF a Strong ETF Right Now?

  The article discusses the First Trust Small Cap Growth AlphaDEX ETF (FYC), analyzing its performance, risk profile, and comparing it to other small-cap growth ETFs. It suggests that FYC is a reasonable option for investors seeking to outperform the small-cap growth market segment, but there are other potentially cheaper and lower-risk alternatives to consider.

  Benzinga

  Featured Companies: FYC IWO VBK
• Adma Biologics (ADMA) Rises But Trails Market: What Investors Should Know

  Adma Biologics (ADMA) stock rose 0.82% in the latest market close, lagging the S&P 500's 1.08% gain. The company is expected to report earnings of $0.08 per share, representing a 500% year-over-year growth, and revenue of $87.03 million, up 44.75% from the prior-year quarter.

  Zacks Investment Research
• Wall Street Breakfast: The Week Ahead

  Stay updated on Wall Street news with our daily podcast available on Seeking Alpha, iTunes, and Spotify.

  Seeking Alpha

  Featured Companies: ACN BFH CBUS CRMT DRI EBAY FDS GME IREN KBH KMX KR KROS LEN LZB MAXN MDB NNE NVRI ORA PAL PATH PSTG QGEN SVCO TRUP WMT